Genome Pharmaceuticals (Pvt.) Ltd.
Private pharmaceutical manufacturer · Rawalpindi · Pakistan
Pakistan pharmaceutical manufacturer with a Hattar production facility and activities spanning manufacturing, marketing, import and export of specialized medicines.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical manufacturer
- Address
- Plaza #63, Wallayat Complex, Opposite Anarkali, Bahria Town Phase 7, Rawalpindi, Pakistan
- Website
- genomepharmaceuticals.com ↗
- Phone
- +92 51 5172521
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Acetin | Acitretin | 10 mg | Capsule | 3 x 10's | 064012 | PKR 1,194.70 | PKR 39.82/capsule | Near median |
| Acetin | Acitretin | 25 mg | Capsule | 3 x 10's | 064013 | PKR 2,698.37 | PKR 89.95/capsule | Near median |
| Akric | Clarithromycin | 125 mg/5 mL | Dry suspension | 60ml | 075532 | PKR 444.78 | PKR 7.41/mL | Near median |
| Akric | Clarithromycin | 250 mg/5 mL | Dry suspension | 60ml | 097282 | PKR 759.96 | PKR 12.67/mL | 12% above median |
| Akric XL | Clarithromycin | 500 mg | Extended-release tablet | 1 x 10's | 064009 | PKR 825.73 | PKR 82.57/tablet | Near median |
| Akric XL | Clarithromycin | 500 mg | Prolonged-release tablet | 1 x 10's | 064009 | PKR 825.73 | PKR 82.57/tablet | 10% below median |
| Akric-250 | Clarithromycin | 250 mg | Tablet | 1 x 10's | 043312 | PKR 478.68 | PKR 47.87/tablet | Near median |
| Akric-500 | Clarithromycin | 500 mg | Tablet | 1 x 10's | 043313 | PKR 887.56 | PKR 88.76/tablet | 6% above median |
| Anabrec | Anastrozole | 1 mg | Tablet | 2 x 14's | 085890 | PKR 9,549.70 | PKR 341.06/tablet | Near median |
| Arefed | Deferasirox | 250 mg | Tablet | 28's | 085092 | PKR 9,521.13 | PKR 340.04/tablet | 13% above median |
| Arefed | Deferasirox | 500 mg | Tablet | 28's | 085093 | PKR 15,803.42 | PKR 564.41/tablet | 8% above median |
| Arefed | Deferasirox | 180 mg | Tablet | 30's | 116110 | PKR 7,153.13 | PKR 238.44/tablet | 31% below median |
| Arefed | Deferasirox | 360 mg | Tablet | 30's | 116111 | PKR 11,920.55 | PKR 397.35/tablet | 32% below median |
| Arthrit-200mg | Hydroxychloroquine | 200 mg | Tablet | 3 x 10's | 087019 | PKR 538.52 | PKR 17.95/tablet | 24% above median |
| Artiminum | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 2 x 8's | 059389 | PKR 638.24 | PKR 39.89/tablet | Near median |
| Artiminum DS | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 1 x 4's | 069719 | PKR 438.79 | PKR 109.70/tablet | Near median |
| Artiminum Forte | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 1 x 8's | 059390 | PKR 526.55 | PKR 65.82/tablet | Near median |
| Artiquin | Artesunate + Mefloquine | 100 mg + 250 mg | Tablet | 3 + 3's | 069798 | PKR 219.40 | — | No comparator |
| Atfromin XR-750 | Metformin | 750 mg | Extended-release tablet | 3 x 10's | 082525 | PKR 112.77 | PKR 3.76/tablet | 11% below median |
| ATM | Artemether + Lumefantrine | 40 mg + 240 mg | Dispersible tablet | 1 x 8's | 064004 | PKR 526.55 | PKR 65.82/tablet | Near median |
| Atractin-10 | Isotretinoin | 10 mg | Capsule | 1 x 10's | 053576 | PKR 751.84 | PKR 75.18/capsule | Near median |
| Atractin-20 | Isotretinoin | 20 mg | Capsule | 3 x 10's | 053577 | PKR 3,810.67 | PKR 127.02/capsule | Near median |
| Avimet | Metronidazole + Iodoquinol (diiodohydroxyquinoline) | 250 mg + 325 mg | Tablet | 10 x 10's | 074531 | PKR 398.90 | PKR 3.99/tablet | No comparator |
| Azilla-250 | Azithromycin | 250 mg | Capsule | 1 x 10's | 046176 | PKR 508.60 | PKR 50.86/capsule | Near median |
| Azilla-500 | Azithromycin | 500 mg | Capsule | 1 x 3's | 074557 | PKR 249.31 | PKR 83.10/capsule | Near median |
| Belstra | Anastrozole | 1 mg | Tablet | 30's | 084179 | PKR 11,010.73 | PKR 367.02/tablet | 8% above median |
| Belstra | Anastrozole | 1 mg | Tablet | 10's | 084179 | PKR 3,989.39 | PKR 398.94/tablet | 17% above median |
| BPR | Bisoprolol fumarate | 5 mg | Tablet | 2 x 10's | 088009 | PKR 249.31 | PKR 12.47/tablet | 6% above median |
| BPR | Bisoprolol fumarate | 2.5 mg | Tablet | 1 x 14's | 088010 | PKR 59.84 | PKR 4.27/tablet | Near median |
| BPR | Bisoprolol fumarate | 10 mg | Tablet | 2 x 10's | 088011 | PKR 448.76 | PKR 22.44/tablet | Near median |
| Butrin | Bupropion | 75 mg | Tablet | 2 x 10's | 068381 | PKR 434.16 | PKR 21.71/tablet | Near median |
| Butrin | Bupropion | 150 mg | Tablet | 3 x 10's | 068382 | PKR 976.86 | PKR 32.56/tablet | Near median |
| Butrin | Bupropion | 300 mg | Tablet | 3 x 10's | 068383 | PKR 2,546.35 | PKR 84.88/tablet | 84% above median |
| Calfoli | Calcium folinate (folinic acid) | 50 mg | Lyophilized powder for injection | 1's | 115708 | PKR 957.44 | PKR 957.44/vial/unit | No comparator |
| Carbapin | Carbamazepine | 200 mg | Tablet | 5 x 10's | 022329 | PKR 540.84 | PKR 10.82/tablet | Near median |
| Cefgen | Cefixime | 400 mg | Capsule | 1 x 5's | 054648 | PKR 591.98 | PKR 118.40/capsule | Near median |
| Cefgen | Cefixime | 100 mg/5 mL | Suspension | 30ml | 054649 | PKR 330.36 | PKR 11.01/mL | Near median |
| Cefgen | Cefixime | 200 mg/5 mL | Suspension | 30ml | 054650 | PKR 404.28 | PKR 13.48/mL | Near median |
| CHC Plus-400mg | Sofosbuvir | 400 mg | Tablet | 28's | 095153 | PKR 19,413.15 | PKR 693.33/tablet | 62% above median |
| CHC-400 | Sofosbuvir | 400 mg | Tablet | 4 x 7's | 080182 | PKR 11,391.64 | PKR 406.84/tablet | 6% below median |
| Cillamin-250 | Penicillamine | 250 mg | Tablet | 1 x 10's | 083802 | PKR 1,048.09 | PKR 104.81/tablet | 250% above median |
| Cipfas | Ciprofloxacin | 250 mg | Capsule | 1 x 10's | 060884 | PKR 259.29 | PKR 25.93/capsule | Near median |
| Cipfas | Ciprofloxacin | 500 mg | Capsule | 1 x 10's | 060885 | PKR 428.82 | PKR 42.88/capsule | Near median |
| Cipvax | Ciprofloxacin | 750 mg | Tablet | 1 x 10's | 059383 | PKR 359.01 | PKR 35.90/tablet | 10% below median |
| CipvaxSource observed | Ciprofloxacin | 125 mg | Held for normalizationSource reported: Tablet · structural field conflict | 60ml | 074529Official source ↗ | No indexed price | — | — |
| Cipvax | Ciprofloxacin | 500 mg | Tablet | 1 x 10's | 080983 | PKR 518.57 | PKR 51.86/tablet | 21% above median |
| Cipvax XR-500 | Ciprofloxacin | 500 mg | Extended-release tablet | 1 x 10's | 080983 | PKR 518.57 | PKR 51.86/tablet | Near median |
| Cipvax-250 | Ciprofloxacin | 250 mg | Tablet | 1 x 10's | 052916 | PKR 259.29 | PKR 25.93/tablet | Near median |
| Cipvax-500 | Ciprofloxacin | 500 mg | Tablet | 1 x 10's | 043310 | PKR 518.57 | PKR 51.86/tablet | 21% above median |
| Clobis | Clopidogrel | 75 mg | Tablet | 1 x 10's | 042518 | PKR 279.23 | PKR 27.92/tablet | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.